phrykt

Quest Diagnostics Inc (DGX): who owns it and who trades it

As of Nov 16, 2026, DGX insiders reported 42 open-market sales worth $48.8M and no purchases in the last 12 months, with 98% of the sale value made under pre-set 10b5-1 plans. The largest seller was J. E. Davis (CEO), with $17.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Quest Diagnostics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DGX

1,102 funds and institutions reported DGX shares worth $22.3B at the end of Q2 2026, about 95% of the company. The largest holder is BlackRock, Inc. with 8.4%.

Funds and institutions (13F) 95%Everyone else 5%

10 largest owners, by share of the company

BlackRock, Inc.8.4%
Vanguard Capital Management LLC6.5%
Vanguard Portfolio Management LLC5.5%
State Street Corp5.0%
T. Rowe Price Associates4.9%
Boston Partners4.3%
JPMorgan Chase & Co3.2%
Geode Capital Management, LLC2.8%
Morgan Stanley2.2%
EdgePoint Investment Group Inc.2.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.9.28M8.38%$2B+1%
Vanguard Capital Management LLC7.23M6.53%$1.5B+1%
Vanguard Portfolio Management LLC6.13M5.54%$1.3B+1%
State Street Corp5.52M4.98%$1.2B+3%
T. Rowe Price Associates5.44M4.92%$1.2B-14%
Boston Partners4.74M4.29%$1B+18%
JPMorgan Chase & Co3.52M3.18%$749M–
Geode Capital Management, LLC3.14M2.83%$663M+2%
Morgan Stanley2.46M2.22%$522M-1%
EdgePoint Investment Group Inc.2.25M2.03%$476M+0%
Dimensional Fund Advisors LP1.99M1.80%$421M+2%
Bank of America Corp1.94M1.75%$410M+10%
Grantham, Mayo, Van Otterloo & Co. LLC1.89M1.71%$400M+0%
Wells Fargo & Company1.75M1.58%$371M-1%
Davis Selected Advisers1.56M1.41%$330M-4%
Victory Capital Management Inc1.55M1.40%$329M-16%
Norges Bank1.41M1.27%$298M–
FMR LLC (Fidelity)1.40M1.26%$296M+48%
Invesco Ltd.1.38M1.25%$292M-16%
Northern Trust Corp1.13M1.02%$239M+1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DGX insiders reported $0 of open-market purchases and $48.8M of sales. 98% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$48.8M
42 trades, 9 people
Sales under a 10b5-1 plan
98%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$11.6M$11.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Michael J DeppeVice presidentSale plan6,261$260.17$1.6MForm 4
Nov 13, 2026Michael J DeppeVice presidentSale plan5,515$260.17$1.4MForm 4
Nov 9, 2026Patrick PlewmanVice presidentSale plan4,274$257.34$1.1MForm 4
Nov 9, 2026Patrick PlewmanVice presidentSale plan6,793$257.34$1.7MForm 4
Nov 9, 2026Patrick PlewmanVice presidentSale plan650$257.34$167KForm 4
Nov 3, 2026Catherine T. DohertyVice presidentSale plan3,818$245.45$937KForm 4
Nov 3, 2026Catherine T. DohertyVice presidentSale plan5,990$246.26$1.5MForm 4
Nov 3, 2026Catherine T. DohertyVice presidentSale plan1,151$246.98$284KForm 4
Nov 3, 2026Catherine T. DohertyVice presidentSale plan2,358$248.38$586KForm 4
Nov 3, 2026Catherine T. DohertyVice presidentSale plan3,004$249.40$749KForm 4
Nov 3, 2026Catherine T. DohertyVice presidentSale plan2,877$250.49$721KForm 4
Nov 3, 2026Catherine T. DohertyVice presidentSale plan2,907$251.24$730KForm 4
Oct 26, 2026Gary M PfeifferDirectorSale plan1,203$243.00$292KForm 4
Sep 1, 2026J. E. DavisCEOSale plan10,000$242.72$2.4MForm 4
Aug 28, 2026Michael E PrevoznikVice presidentSale plan430$244.51$105KForm 4
Aug 28, 2026Michael E PrevoznikVice presidentSale plan6,237$243.63$1.5MForm 4
Aug 28, 2026Michael E PrevoznikVice presidentSale plan16,010$242.88$3.9MForm 4
Jul 28, 2026Mark E DelaneyVice presidentSale plan1,600$235.18$376KForm 4
Jun 4, 2026Karthik KuppusamyVice presidentSale plan8,147$200.00$1.6MForm 4
Jun 1, 2026J. E. DavisCEOSale plan10,000$194.14$1.9MForm 4
Mar 5, 2026Catherine T. DohertyVice presidentSale plan5,558$206.21$1.1MForm 4
Mar 5, 2026Michael E PrevoznikVice presidentSale plan3,878$206.21$800KForm 4
Mar 5, 2026Patrick PlewmanVice presidentSale plan2,855$206.21$589KForm 4
Mar 4, 2026Karthik KuppusamyVice presidentSale2,628$204.86$538KForm 4
Mar 3, 2026Catherine T. DohertyVice presidentSale plan632$207.73$131KForm 4
Mar 3, 2026Michael E PrevoznikVice presidentSale plan526$207.73$109KForm 4
Mar 3, 2026Patrick PlewmanVice presidentSale plan410$207.73$85.2KForm 4
Mar 2, 2026J. E. DavisCEOSale plan10,000$212.52$2.1MForm 4
Feb 19, 2026Patrick PlewmanVice presidentSale plan958$204.83$196KForm 4
Feb 19, 2026Michael E PrevoznikVice presidentSale plan1,111$204.83$228KForm 4
Feb 19, 2026Catherine T. DohertyVice presidentSale plan1,433$204.83$294KForm 4
Feb 13, 2026Catherine T. DohertyVice presidentSale plan10,122$206.37$2.1MForm 4
Feb 13, 2026Catherine T. DohertyVice presidentSale plan10,573$205.21$2.2MForm 4
Feb 13, 2026Catherine T. DohertyVice presidentSale plan351$209.10$73.4KForm 4
Feb 13, 2026Catherine T. DohertyVice presidentSale plan1,619$208.21$337KForm 4
Feb 13, 2026Catherine T. DohertyVice presidentSale plan3,500$207.08$725KForm 4
Feb 10, 2026Patrick PlewmanVice presidentSale plan5,662$204.00$1.2MForm 4
Nov 25, 2025J. E. DavisCEOSale plan9,342$191.59$1.8MForm 4
Nov 25, 2025J. E. DavisCEOSale plan4,747$192.97$916KForm 4
Nov 25, 2025J. E. DavisCEOSale plan41,004$192.27$7.9MForm 4
Nov 25, 2025Vicky B GreggDirectorSale1,250$191.76$240KForm 4
Nov 18, 2025Mark E DelaneyVice presidentSale plan7,946$187.35$1.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
J. E. DavisCEO and President, Director–$17.1MSep 1, 2026
Catherine T. DohertyEVP, Regional Businesses–$12.4MNov 3, 2026
Michael E PrevoznikSVP & General Counsel–$6.6MAug 28, 2026
Patrick PlewmanSVP for Diagnostic Services–$5MNov 9, 2026
Michael J DeppeSVP, Corp. Controller & CAO–$3.1MNov 13, 2026
Karthik KuppusamySVP, Clinical Solutions–$2.2MJun 4, 2026
Mark E DelaneySVP & Chief Commercial Officer–$1.9MJul 28, 2026
Gary M PfeifferDirector–$292KOct 26, 2026
Vicky B GreggDirector–$240KNov 25, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DGX short interest

Low short interest. 3.4% of DGX shares are sold short: about 1 share in 29. Over the last 12 reports the number of shares short went up 1%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.73M DGX shares were sold short, 3.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 3.6 trading days (days to cover).

Shares short, % of all shares

3.39%May 15Oct 303.45%

Days to cover

3.6May 15Oct 305.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.73M3.39%+4%1.02M3.6
Oct 15, 20263.57M3.25%+5%1.06M3.4
Sep 30, 20263.42M3.10%-5%1.27M2.7
Sep 15, 20263.60M3.26%+4%975,5623.7
Aug 31, 20263.45M3.12%+4%893,6993.9
Aug 14, 20263.32M3.01%-10%711,5124.7
Jul 31, 20263.68M3.34%+5%1.34M2.7
Jul 15, 20263.51M3.18%-6%823,8474.3
Jun 30, 20263.73M3.37%+9%971,1603.8
Jun 15, 20263.42M3.09%-0%802,9044.3
May 29, 20263.43M3.10%-8%822,1734.2
May 15, 20263.72M3.36%+10%744,7985.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded DGX

Since Nov 17, 2024, 4 members of Congress reported 4 purchases and 5 sales of DGX. The latest was a purchase by Alan Armstrong on Mar 30, 2026, reported Jul 21, 2026.

Purchases 4Sales 5

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Mar 30, 2026Alan Armstrong (R-OK)Purchase$1K–$15KSelfJul 21, 2026Report
Mar 27, 2026Alan Armstrong (R-OK)Purchase$1K–$15KSelfJul 21, 2026Report
Nov 3, 2025Julie Johnson (D-TX)Sale$1K–$15KJointDec 11, 2025Report
Oct 30, 2025Julie Johnson (D-TX)Sale$1K–$15KJointAug 5, 2026Report
Oct 30, 2025Julie Johnson (D-TX)Purchase$1K–$15KJointAug 5, 2026Report
Jul 24, 2025Julia Letlow (R-LA)Sale$1K–$15KSelfJan 13, 2026Report
Apr 28, 2025Julia Letlow (R-LA)Purchase$1K–$15KSelfJan 13, 2026Report
Mar 10, 2025Carol D. Miller (R-WV)Sale$15K–$50KSpouseAug 13, 2026Report
Mar 10, 2025Carol D. Miller (R-WV)Sale$1K–$15KSelfApr 11, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Quest Diagnostics company events

Quest Diagnostics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 22, 2026.

  1. Oct 22, 2026AnnouncementQuest Diagnostics Incorporated learned of unauthorized access to its Quanum LSM system, which certain clients use to place test orders, receive and look up results. Filing
  2. Oct 22, 2026ResultsReleased financial results. Filing
  3. Oct 6, 2026LeadershipQuest Diagnostics Incorporated announced that Catherine T. Doherty will retire in July 2027. Filing
  4. Jul 23, 2026ResultsReleased financial results. Filing
  5. May 21, 2026VoteReported shareholder vote results. Filing
  6. May 8, 2026AgreementQuest Diagnostics Incorporated issued $500 million of 5.000% senior notes due 2036. Filing
  7. May 1, 2026AnnouncementQuest Diagnostics Incorporated issued a press release announcing the pricing of a public offering of $500 million of its 5.000% senior notes due 2036 under the Company’s shelf registration statement. Filing
  8. Apr 21, 2026ResultsReleased financial results. Filing
  9. Mar 12, 2026LeadershipThe Board of Directors of Quest Diagnostics Incorporated, after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. Filing
  10. Feb 10, 2026AnnouncementThe Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per share. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Quest Diagnostics financials

Famous investors that hold DGX

4 of the 50 well-known investors we track reported holding DGX in their latest 13F filing. The largest position is Jeremy Grantham's, worth $450M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jeremy Grantham · GMOQ3 20261.93M$450M1.0%+2%
Ken Griffin · Citadel AdvisorsQ3 2026431,647$101M0.1%+224%
Israel Englander · Millennium ManagementQ3 2026117,532$27.4M0.0%+928%
Ray Dalio · Bridgewater AssociatesQ3 20263,548$827K0.0%-6%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DGX in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G5.0%
Nov 10, 2026STATE STREET CORPORATION13G5.0%

Questions about Quest Diagnostics Inc (DGX) stock

Who owns the most DGX stock?

The largest reported owner of Quest Diagnostics Inc (DGX) is BlackRock, Inc., with 8.4% of the company. In total, 1,102 funds and institutions reported holding DGX at the end of Q2 2026, together about 95% of the shares. See the largest owners.

Are DGX insiders buying or selling?

In the last 12 months, DGX insiders reported no open-market purchases and 42 sales worth $48.8M. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in DGX?

As of Oct 30, 2026, 3.73M DGX shares were sold short, 3.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 3.6 trading days (days to cover). See the history.

Have members of Congress traded DGX?

Yes. 4 members of Congress reported 4 purchases and 5 sales of DGX since Nov 17, 2024. The latest was reported on Aug 13, 2026. See the trades.

Which famous investors hold DGX?

4 of the 50 well-known investors we track reported DGX in their latest 13F filing, including Jeremy Grantham, Ken Griffin, Israel Englander. The largest position is worth $450M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.